RxDoctor Payments DataLook up a doctor →

Katherine Hunt, MD

Dermatology · Hoover, ALNPI 1477932192

Payments from drug & device makers

$11,874in general payments, 2019–2025

Across 631 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Lilly USA, LLC$879
  • Mayne Pharma Commercial LLC$792
  • Sun Pharmaceutical Industries Inc.$732
  • Galderma Laboratories, L.p.$638
  • plus $5K from 27 others

What the payments were for

  • Food & beverage$11,78699%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,874 in reported general payments places this provider in the 70th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$153,803
Medicare patients
427
Services billed
2,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab61$224,663
Skyrizi PenRisankizumab-Rzaa11$219,723
Dupixent SyringeDupilumab22$156,180
Cosentyx Unoready PenSecukinumab11$97,415
Cosentyx (2 Syringes)Secukinumab12$86,620
Taltz AutoinjectorIxekizumab11$75,080
Clobetasol Propionate82$3,938
Ketoconazole131$3,301
Betamethasone Dipropionate70$3,246
Tacrolimus22$2,415
Fluorouracil33$2,413
ValacyclovirValacyclovir Hcl59$1,728
Acitretin11$1,641
Dapsone12$1,629
Triamcinolone Acetonide93$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$1,143$86,62012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 168 dermatology providers in Alabama.

Other dermatology in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →